匯豐保險:去年新造人壽業務保費市場份額位列第一
保監局公布去年保險業統計數字,匯豐保險香港行政總裁文德華表示,保險業監管局公布的臨時統計數據顯示,去年下半年度,匯豐保險的新造人壽業務保費的市場份額位列第一。去年透過銀行渠道銷售的保費佔新造人壽業務保費總額的48%,依然是本港人壽保險最主要的銷售渠道。儘管去年下半年本港市場極具挑戰,匯豐保險的新造人壽業務保費總額仍創下新高,充分體現匯豐銀行保險營運模式獨一無二的優勢,為客戶提供全面的保障和財務解決方案。
他表示,在當前波動及充滿不確定性的市場下,保險作為一個可抵禦衝擊投資工具的重要性不言而喻。該行將透過包含會面、數碼渠道及遠程服務的多元化渠道,繼續為客戶提供適當的保險產品,以滿足其對保障、財富積累及退休的需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.